The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering.This analysis examines the global clinical chemistry and immunoassay ...

The identification of genes involved in diseases is one of the major challenges of biomedical research. Researchers at the ...

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

Clinical uses of mass spectrometry have historically been limited to specialist facilities. A new solution from Roche ...

Roche introduces cobas Mass Spec solution, bringing mass spectrometry to the routine clinical lab: Basel Thursday, December 19, 2024, 09:00 Hrs [IST] Roche announced that it has r ...

The identification of genes involved in diseases is one of the major challenges of biomedical research. Researchers at the ...

The system includes the Cobas I 601 analyzer and the first Ionify reagent pack of four assays for steroid hormones.

Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials - ...

on-target changes in hematology and clinical chemistry parameters that resolved completely within 14 to 21 days post-dosing. A significant increase in interferon gamma (IFNγ), which was controlled and ...

Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...

Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the ...